CHICAGO, July 16 (Reuters) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety ...

Today’s businesses need to adapt faster than ever, global competition is fierce and, according to a recent article in the New York Times, retirement rates are accelerating. The next generation of ...

Acumen Nephrology has introduced its new practice management product, Acumen® PM, which offers a full suite of options to streamline the practice of nephrology. Following great success with its ...

An experimental Alzheimer’s disease drug developed by Acumen Pharmaceuticals ABOS.O targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance ...